Precision Oncology Today
Bispecific antibodies show promise in delivering immunotherapy with limited side effects and high response rates.
Three therapeutic regulatory approvals in less than a year signal that the promise of the human microbiome may finally be paying off. All of...
Trending on Inside Precision Medicine
Researchers have presented a new technique to identify drug targets linked to abnormal protein phase separation in diseases such as Alzheimer's.
Takeda and AcuraStem will jointly develop and commercialize AcuraStem's PIKFYVE targeted therapeutics for neurodegenerative diseases including ALS and frontotemporal dementia.
New research led by investigators at Uppsala University in Sweden shows emerging evidence that autologous hematopoietic stem cell transplantation (aHSCT) may be a suitable treatment for relapsing-remitting multiple sclerosis (MS).